BioCentury
ARTICLE | Financial News

Lava raises €16M for gamma delta T cell platform

May 23, 2018 9:12 AM UTC

Lava Therapeutics B.V. ('s-Hertogenbosch, the Netherlands) raised €16 million ($18.8 million) in a series B round led by Gilde Healthcare and Versant Ventures. Also participating were MRL Ventures Fund, Lupus Ventures and Biox Biosciences. Lupus and Biox invested in the company's €1 million series A round last year; the other firms are new investors.

Lava is developing bispecific gamma delta T cells to treat cancer. The company's V-gamma-9V-delta-2 T cells are reactive to small phosphorylated metabolite antigens expressed by tumor cells, which respond to signals from tumors leading to tumor infiltration, interferon (IFN) gamma secretion and tumor cell killing...

BCIQ Target Profiles

Interferon (IFN) gamma